Sanofi bets on its 'high-potential' pipeline; Ipsen preps muscle-spasm drug for review;

@FierceBiotech: With biotech stocks sizzling, drug developers are bringing home the bacon. Story | Follow @FierceBiotech

@JohnCFierce: AstraZeneca adds 550 jobs to the chopping block as profits shrivel. News | Follow @JohnCFierce

@DamianFierce Today in biotech IPOs: Revance, Eleven Biotherapeutics and Egalet raised a combined $196M in their debuts. Read | Follow @DamianFierce

@EmilyMFierce: Global cancer rates expected to hit 22 million new cases per year by 2030, according to WHO. Story via CBS News | Follow @EmilyMFierce

> Despite a stateside setback for Lemtrada, Sanofi ($SNY) is counting on its late-stage pipeline to deliver in 2014, deeming 9 of its 12 Phase III candidates as "high potential." Results (PDF)

> France's Ipsen is planning to file for approval for the muscle-spasm treatment Dysport Next Generation, citing a positive Phase III study. News

> FDA Commissioner Margaret Hamburg is on a voyage to India, meeting with drugmakers and regulators to address mounting quality concerns. Story

Medical Device News

@FierceMedDev: A judge said J&J wrongly eliminated thousands of key vaginal mesh docs. More | Follow @FierceMedDev

@MarkHFierce: Xerox is testing some really interesting patient monitoring tech. Yes, Xerox. Release | Follow @MarkHFierce

@MichaelGFierce: Check out FierceDrugDelivery's special report: The top drug delivery partnerships of 2013. Report | Follow @MichaelGFierce

@EmilyWFierce: GE sells off Breas Medical to PBM Capital. Release | Follow @EmilyWFierce

> Analysts: Rivals may seek to beat Smith & Nephew's $1.7B ArthroCare offer. Story

> St. Jude puts the Nanostim leadless pacemaker in its first U.S. patient. More

Pharma News

@FiercePharma: Pharma giants arm-twist U.S. government for IP action in India. Story | Follow @FiercePharma

@TracyStaton: AstraZeneca, on the other hand, saw Q4/full year 'in line with our expectations,' which means generics are still hitting hard. | Follow @TracyStaton

@EricPFierce: The FDA prescription for fighting counterfeit drugs includes targeting the docs who buy them. More | Follow @EricPFierce

> Generics pull AZ sales back again, but CEO promises a quicker bounce-back. Story

> AstraZeneca steps up its global restructuring with 550 new job cuts. News

> After tougher-than-expected 2013, Sanofi anticipates patent-cliff freedom. More

> Pharma giants arm-twist U.S. government for IP action in India. Piece

Pharma Manufacturing News

> FDA Commissioner Hamburg heads for India to talk about quality manufacturing. News

> As Ranbaxy's plant problems mount, so do its losses. More

> BMS plots major job cuts at plants in France. Story

> AbbVie picks Singapore for a $320M production facility. Article

> 7 Ohio docs pony up $2.6M for buying foreign-made cancer drugs. Piece

> Teva, which has been tightening its supply chain, turns in a surprising financial report. Item

Vaccines News

> GSK is refusing to write off its cancer vaccine despite last year's PhIII flop. Article

> Circassia to test U.K. investors' appetite for risk with a $285M IPO. More

> Buzz: Novartis mulls selling its vaccine unit as swap deal with Merck stalls. Story

> Study: Merck's and GSK's HPV vaccines don't encourage risky sex. Piece

> CDC finds rare cases of nurses injecting GSK's and Merck's oral rotavirus vaccines. News

NIH leaders view HIV vaccine as essential to ending AIDS pandemic. Item

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.